Snehal Patel, Greenwich LifeSciences CEO
July 12, 2022 10:43 AM EDT
Pharma
FDA+
Manufacturing

FDA lifts hold on Green­wich Life­Sciences as biotech will forge ahead with im­munother­a­py drug can­di­date

Tyler Patchen

News Reporter

While the bear mar­ket still has its hold over the biotech sec­tor, Green­wich Life­Sciences is wel­com­ing the lat­est news from the FDA.

The biotech an­nounced …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times